The publication in 2001 of a White Paper on a new European Union (EU) initiative, entitled Strategy for a Future Chemicals Policy, 1 has caused great concern among scientists and animal welfare groups about a possibly huge increase in the use of laboratory animals to cope with the further testing of some 30,000 existing chemicals in use in the EU. Also, a burden has been placed on chemical manufacturers and downstream users (for example, companies that use chemicals as ingredients in the manufacture of other products) to provide hazard data and to undertake separate risk assessments, as part of the overall process of risk management.
Emerging scientific and logistic concerns, together with recent changes in policy at the European Parliamentary level, have led to great confusion as to how and when the recommendations in the White Paper are going to be implemented.
The EU is promoting the implementation of the policy as part of its plans for a "risk-free" environment. This is plainly a non-scientific approach, since such a Utopian dream is unattainable, as it requires the calculation and exclusion of risk in every conceivable situation. Certain Member States seem very keen to endorse the policy. For example, the Copenhagen Charter on Safer Chemicals calls for the safety assessment of all chemicals, to ensure that their use is safe beyond reasonable doubt.
As far as the European Commission (EC) is concerned, the policy is ready for implementation, and although nothing can stop something happening, there is plenty of scope for other bodies to help and advise over how the system will operate in practice. Arrangements for the collection and analysis of the data are still being finalised. The original idea was for the European Chemicals Bureau (ECB) at Ispra to be expanded, to cope with the extra toxicity information. However, there is also a possibility that this will be undertaken at a new centre to be established in Austria. Wherever this happens, it has been estimated that at least 200 new EC personnel will be needed to cope with the extra workload.
The timetable for testing has been set by the EC in relation to the numbers of chemicals produced in amounts of less than 3,000 tonnes a year; 3,000-10,000 tonnes a year; and 10,000-30,000 tonnes a year. The EC believes that industry already holds much of the essential data on existing chemicals, and that individual companies need to be encouraged (or even compelled) to share this information. However, this schedule might well have to be altered, because several legal issues need to be resolved before the policy can proceed. These issues include the establishment of a legal framework that can compel industry to cooperate. It has even been suggested that the legal process could take several years to complete, although the EC may be required by other forces to simply press ahead regardless.
At a conference of stakeholders to discuss the implications of the White Paper, all present agreed that animal numbers should be minimised as far as possible, and that one way to achieve this would be the increased use of alternative methods. However, although the need to use alternatives is promoted in the White Paper, there is no defined strategy to facilitate this process. Meanwhile, a group of MPs at Westminster have put forward an amendment 2 to an early-day motion in the House of Commons to support the Copenhagen Charter. In this amendment, the MPs point out that, under the Charter, many thousands of laboratory animals will be sacrificed to test chemicals that have proved to be safe in use over a considerable time. They suggest that the testing programme should be focused on chemicals for which there is good reason to suspect possible adverse effects.
As a consequence of these scientific and animal welfare concerns, the EC has asked the European Centre for the Validation of Alternative Methods (ECVAM) to propose a way forward for the application of existing alternative methods, and to identify those methods that have potential for use, once they have been validated. ECVAM was also asked to identify areas of research that should facilitate the development of new methods in areas of testing that now have to be undertaken by using animals. It has therefore been largely left to the Joint Research Centre (JRC), through ECVAM, to press for a greater focus on the use of alternatives to be part of the overall testing strategy. To this end, ECVAM has established a working group on chemicals, with ten members from various EU Member States (four from the UK, three from Germany, one from the Netherlands and two from Italy), representing experts from industry, academia and welfare groups, and chaired by Michael Balls (ECVAM and FRAME).
The meetings of the ECVAM working group are focused on the use of alternative methods for iden-tifying chemicals that are potentially hazardous to humans, with a view to the development of an integrated testing strategy for existing chemicals. The first of these meetings, held in February 2001, and attended by Richard Clothier (FRAME Alternatives Laboratory, University of Nottingham), resulted in the production of an outline testing approach based on ECITTS, the ERGATT/CFN Integrated Toxicity Testing Scheme. This involves modelling the fate of chemicals after they enter the body by various routes of exposure, to predict major target organs, the concentrations of chemicals at these sites, rates of interaction with target cells and tissues, metabolism and excretion. This information is used in conjunction with the results of in vitro determinations of general and tissue-type specific cytotoxicity to cells of the target organs.
Ten experts, including Robert Combes (FRAME), attended the second meeting, held in July. The task of this meeting was to assess the feasibility of implementing the outline scheme developed at the earlier meeting. In particular, the nature of the detailed information required to operate an integrated testing scheme was identified in relation to the status of alternative methods for each of the toxicity endpoints that are required for the base-set testing of new chemicals. The suggested approach includes the use of prior physicochemical, toxicity and exposure information, and quantitative structure-activity relationships, together with testing with specific cell-culture systems to determine both the basal cytotoxicities and the metabolism profiles of chemicals. It was suggested that the existing chemicals identified for testing, first need to be grouped according to chemical class, solubility and structure. The importance was stressed of feeding all this information, together with any new toxicity data, into databases, with the aim of continuously improving computer-based prediction systems.
In the meantime, based on discussions at this meeting and written contributions from members of the working group and other members of ECVAM's network of collaborators, ECVAM has produced the first draft of a comprehensive strategy document that is intended to provide an introduction to the EU chemicals policy, then to describe an integrated testing approach to assessing potential hazard to humans from exposure to chemicals, together with a survey of the current state of nonanimal approaches for chemicals testing. The strengths and weaknesses of each of the alternative tests are discussed. Where necessary, key recommendations for improving existing methods and developing new ones are made in relation to short-, medium-and long-term priorities, and with reference to the schedule for implementing the policy that has been recommended by the EC.
A third meeting of the group took place in Munich at the beginning of October 2001, to discuss the draft strategy document produced by ECVAM, as a result of which it will be augmented with the inclusion of several flow diagrams and decisiontrees. The report will also be prefaced by a detailed discussion of a recommended overall strategy for testing.
Meanwhile the EC has requested nominations for experts to serve on several official working groups to help it implement the new chemicals policy. The main issues to be covered by the working groups are: risk assessment; testing, registration and evaluation; classification and labelling; risk management; the testing of substances and products; and information from the supply chain. ECVAM is represented on the second of these groups. The idea is that each Member State will have a representative on each group, together with other representatives of the principal stakeholders, including industry.
A timetable has been set for the work of the ECVAM Chemicals Working Group. Early in 2001, the group will hold another meeting, and will also present the recommendations in its strategy document to representatives of the principal stakeholders. Following further modification, it is intended to publish the document as a special issue of ATLA, shortly after Easter 2002. The overall aim is to produce a scheme that will maximise the use of nonanimal approaches for the testing of existing chemicals within the EU, without compromising human safety.
However, two recent events that occurred in the European Parliament look set to complicate the implementation of the EU Chemicals Policy even further. Indeed, it seems that those who voiced widespread concern regarding the shortcomings of the policy and its implications for laboratory animal welfare, have at last been listened to.
The first of these events occurred on 16 October 2001, when the European Parliament's Environment Committee adopted a series of recommendations in a draft report prepared by Inger Schörling MEP. These recommendations include most, if not all, of those that have previously been suggested by FRAME, and which are aimed at reducing to a minimum the numbers of animal tests required, while promoting the development of more alternative methods. Most importantly, the report also proposes that a simplified system for risk assessment should be used, based on high quality information on human and environmental exposure. In addition, the report calls for the disclosure and sharing of data to be promoted and coordinated.
The second event occurred on 15 November 2001, when the European Parliament voted to weaken its own proposals. It seems that the Parliament has agreed to exclude very persistent and recalcitrant chemicals, and endocrine disruptors, from the proposed authorisation system.
